Nuwellis (NUWE) Stock Price, News & Analysis

Company Overview

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting. This technology is used in hospitals, specialty renal centers and other acute care facilities. The system’s design emphasizes ease of use for clinicians, with automated control features and real‐time monitoring that support individualized treatment plans and help mitigate the risks associated with rapid fluid shifts.

Originally founded as Renal Solutions in 2005, the company adopted the Nuwellis name in 2016 to reflect a broader commitment to advancing fluid management therapies. Headquartered in Plymouth, Minnesota, Nuwellis holds both FDA clearance in the United States and CE Mark approval for distribution across Europe. Its sales and distribution network serves acute care hospitals and renal clinics across North America and select international markets.

Nuwellis continues to invest in research and development aimed at expanding the clinical applications of its ultrafiltration technology. The company’s leadership team includes seasoned executives with extensive experience in medical devices and healthcare innovation. Ongoing efforts focus on regulatory approvals, commercial partnerships and clinical studies to validate new indications and broaden access to its therapies worldwide.

Key Stats

• Today's Range: $1.00 to $1.06
• 50-Day Range: $1.01 to $1.56
• 52-Week Range: $0.96 to $43.18
• Volume: 27,779 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $2.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Nuwellis Stock Analysis - MarketRank™

Nuwellis scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Nuwellis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nuwellis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuwellis has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.90% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 1.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently increased by 41.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuwellis does not currently pay a dividend.

Dividend Growth

Nuwellis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.62

News Sentiment

Nuwellis has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Nuwellis this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuwellis insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Nuwellis is held by insiders.

Percentage Held by Institutions

3.13% of the stock of Nuwellis is held by institutions.

Company Calendar

• Last Earnings: 3/10/2026
• Today: 5/12/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NUWE
• CIK: 1506492
• Web: www.nuwellis.com
• Phone: (952) 345-4200
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($90.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.52 million
• Net Margins: -211.86%
• Pretax Margin: -211.80%
• Return on Equity: -6,094.26%
• Return on Assets: -231.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $8.27 million
• Price / Sales: 0.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.58 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 2,461,000
• Free Float: 2,422,000
• Market Cap: $2.50 million
• Optionable: Not Optionable
• Beta: 0.25